COSMOS Pharmaceutical Corporation (JP:3349)
:3349
3349 Stock Chart & Stats
¥6699.00
¥109.00(1.60%)
At close: 4:00 PM EST
¥6699.00
¥109.00(1.60%)
Day’s Range― - ―
52-Week Range¥6,355.00 - ¥10,045.00
Previous CloseN/A
Volume659.40K
Average Volume (3M)399.89K
Market Cap
¥530.69B
Enterprise Value¥525.27B
Total Cash (Recent Filing)¥57.04B
Total Debt (Recent Filing)¥49.96B
Price to Earnings (P/E)22.8
Beta-0.21
Next Earnings
Apr 13, 2026EPS Estimate
98.04Next Dividend Ex-DateN/A
Dividend Yield0.93%
Share Statistics
EPS (TTM)81.73
Shares Outstanding80,001,600
10 Day Avg. Volume586,980
30 Day Avg. Volume399,893
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)2.72
Price to Sales (P/S)0.69
P/FCF Ratio-814.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)399.93
Revenue Forecast (FY)¥1.08T
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained revenue expansion reflects durable consumer demand and successful retail execution across the Cosmos store network. Over 2-6 months this underlying top-line trend supports scale benefits, predictable inventory turnover, and capacity to reinvest in stores and merchandising to deepen market penetration.
Solid Balance Sheet And ROELow leverage and strong ROE provide lasting financial flexibility: the company can fund organic expansion, absorb demand shocks, and negotiate supplier terms without overreliance on external capital. This structural strength supports resilient operations and strategic investments over the medium term.
Stable Margins And Operational EfficiencyConsistent gross/net margins and healthy EBIT/EBITDA margins indicate durable cost controls, merchandising mix strength, and efficient store operations. These fundamentals underpin long-term profitability and provide a buffer against competitive pricing or input-cost fluctuations, sustaining cash generation potential if conversion improves.
Bears Say
Negative Free Cash Flow TrendPersistent negative free cash flow despite profitability signals a cash conversion issue—likely from capex, working capital, or other outflows. Over months this constrains capacity for debt reduction, dividends, or strategic investments unless cash conversion improves or financing is secured, increasing execution risk.
Rising Total Debt To MonitorAn upward trend in total debt, even from a low base, reduces optionality and raises sensitivity to interest-rate or margin shocks. If free cash flow stays negative, incremental borrowing to fund operations could elevate leverage and interest costs, pressuring financial flexibility over the coming quarters.
Slight Decline In EBIT MarginA recent dip in EBIT margin points to rising operating cost pressures or margin mix shifts. If persistent, margin compression will erode operating leverage and reduce the cushion for reinvestment and returns, requiring either price recovery or tighter cost controls to restore long-term profitability.
COSMOS Pharmaceutical Corporation News
3349 FAQ
What was COSMOS Pharmaceutical Corporation’s price range in the past 12 months?
COSMOS Pharmaceutical Corporation lowest stock price was ¥6355.00 and its highest was ¥10045.00 in the past 12 months.
What is COSMOS Pharmaceutical Corporation’s market cap?
COSMOS Pharmaceutical Corporation’s market cap is ¥530.69B.
When is COSMOS Pharmaceutical Corporation’s upcoming earnings report date?
COSMOS Pharmaceutical Corporation’s upcoming earnings report date is Apr 13, 2026 which is in 16 days.
How were COSMOS Pharmaceutical Corporation’s earnings last quarter?
COSMOS Pharmaceutical Corporation released its earnings results on Jan 13, 2026. The company reported ¥81.73 earnings per share for the quarter, missing the consensus estimate of ¥84.01 by -¥2.28.
Is COSMOS Pharmaceutical Corporation overvalued?
According to Wall Street analysts COSMOS Pharmaceutical Corporation’s price is currently Overvalued.
Does COSMOS Pharmaceutical Corporation pay dividends?
COSMOS Pharmaceutical Corporation pays a Semiannually dividend of ¥37.5 which represents an annual dividend yield of 0.93%. See more information on COSMOS Pharmaceutical Corporation dividends here
What is COSMOS Pharmaceutical Corporation’s EPS estimate?
COSMOS Pharmaceutical Corporation’s EPS estimate is 98.04.
How many shares outstanding does COSMOS Pharmaceutical Corporation have?
COSMOS Pharmaceutical Corporation has 80,001,600 shares outstanding.
What happened to COSMOS Pharmaceutical Corporation’s price movement after its last earnings report?
COSMOS Pharmaceutical Corporation reported an EPS of ¥81.73 in its last earnings report, missing expectations of ¥84.01. Following the earnings report the stock price went down -3.795%.
Which hedge fund is a major shareholder of COSMOS Pharmaceutical Corporation?
Currently, no hedge funds are holding shares in JP:3349
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMOS Pharmaceutical Corporation
COSMOS Pharmaceutical Corporation operates a chain of drug stores in Japan. It also operates 1,130 stores in the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. The company was founded in 1983 and is headquartered in Fukuoka, Japan.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
Create SD Holdings Co., Ltd.
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―
Options Prices
Currently, No data available
---